AnaptysBio’s Imsidolimab Meets Yet Another Failure

The latest clinical trial failure of AnaptysBio, Inc.’s interleukin-36 receptor-targeting monoclonal antibody, imsidolimab, means the drug’s utility will stay mostly confined to generalized pustular psoriasis (GPP), where it will nevertheless face strong competition from Boehringer Ingelheim GmbH’s spesolimab. But it also gives the company the chance to shift its focus to other pipeline assets.

AnaptysBio said 31 August that the Phase II HARP trial of imsidolimab in hidradenitis suppurativa (HS) failed to meet its primary endpoint of change from baseline in nodule and abscess (AN) count at week 16 for the drug compared with placebo, as well as missing the key secondary endpoints of mean percent AN count change from baseline and at least 50% lesion count reduction in the